Invivyd, Inc.

NasdaqGM IVVD

Invivyd, Inc. Price to Earnings Ratio (P/E) on February 06, 2025: -1.05

Invivyd, Inc. Price to Earnings Ratio (P/E) is -1.05 on February 06, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Invivyd, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.19 on January 31, 2025, which is 81.93% above the current Price to Earnings Ratio (P/E).
Invivyd, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.12 on February 05, 2025, which is -6.57% below the current Price to Earnings Ratio (P/E).
Invivyd, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.40.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: IVVD

Invivyd, Inc.

CEO	Dr. Robert D. Allen Ph.D.
IPO Date	Aug. 6, 2021
Location	United States
Headquarters	1601 Trapelo Road
Employees	94
Sector	Healthcare
Industries Vaccines Biotechnology Clinical Trials Pharmaceuticals

Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Key trends

Past 5 years